Impaired Wound Healing with Imatinib Mesylate Therapy

Ronicke M, Erfurt-Berge C (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Advances in Skin & Wound Care Lippincott Williams & Wilkins Ltd.

Book Volume: 34

Pages Range: 109-111

Journal Issue: 2

DOI: 10.1097/01.ASW.0000725176.48771.0f

Abstract

ABSTRACT: Medication-induced ulcers are generally rare. Although the tyrosine kinase inhibitor imatinib mesylate is frequently prescribed, the occurrence of ulcers related to the medication has not been previously described. Herein, the authors report a case of a patient with impaired wound healing that was attributed to imatinib mesylate treatment. Providers should maintain suspicion for medication-induced ulcers, particularly if treatment for the presumed underlying cause of an ulcer fails.

Authors with CRIS profile

Moritz Ronicke Department of Dermatology Cornelia Erfurt-Berge Department of Dermatology

How to cite

APA:

Ronicke, M., & Erfurt-Berge, C. (2021). Impaired Wound Healing with Imatinib Mesylate Therapy. Advances in Skin & Wound Care, 34(2), 109-111. https://doi.org/10.1097/01.ASW.0000725176.48771.0f

MLA:

Ronicke, Moritz, and Cornelia Erfurt-Berge. "Impaired Wound Healing with Imatinib Mesylate Therapy." Advances in Skin & Wound Care 34.2 (2021): 109-111.

BibTeX: Download